The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Classic toxin-induced animal models of Parkinson?s disease: 6-OHDA and MPTP
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
6-hydroxy-dopamine induced degeneration of central monoamine neurons
Ungerstedt, U. (1968) · European Journal of Pharmacology · doi:10.1016/0014-2999(68)90164-7 · Cited by 1,460
Chronic parkinsonism secondary to intravenous injection of meperidine analogues
Davis, G. C., Williams, A. C., Markey, S. P., Ebert, M. H., Caine, E. D., Reichert, C. M., & Kopin, I. J. (1979) · Psychiatry Research · doi:10.1016/0165-1781(79)90006-4 · Cited by 1,376
Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290
3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists
CARLSSON, A., LINDQVIST, M., & MAGNUSSON, T. (1957) · Nature · doi:10.1038/1801200a0 · Cited by 1,278
Javitch, J. A., D'Amato, R. J., Strittmatter, S. M., & Snyder, S. H. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.7.2173 · Cited by 1,263
Nicklas, W. J., Vyas, I., & Heikkila, R. E. (1985) · Life Sciences · doi:10.1016/0024-3205(85)90146-8 · Cited by 1,262
Blum, D., Torch, S., Lambeng, N., Nissou, M.-F., Benabid, A.-L., Sadoul, R., & Verna, J.-M. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(01)00003-x · Cited by 1,246
Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo
Tomac, A., Lindqvist, E., Lin, L.-F. H., Ögren, S. O., Young, D., Hoffer, B. J., & Olson, L. (1995) · Nature · doi:10.1038/373335a0 · Cited by 1,079
Functional recovery in parkinsonian monkeys treated with GDNF
Gash, D. M., Zhang, Z., Ovadia, A., Cass, W. A., Yi, A., Simmerman, L., Russell, D., Martin, D., Lapchak, P. A., Collins, F., et al. (1996) · Nature · doi:10.1038/380252a0 · Cited by 955
Chemical sympathectomy by selective destruction of adrenergic nerve endings with 6-hydroxydopamine
Thoenen, H., & Tranzer, J. P. (1968) · Naunyn-Schmiedebergs Archiv f�r Pharmakologie und Experimentelle Pathologie · doi:10.1007/bf00536990 · Cited by 862
Sauer, H., & Oertel, W. H. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90605-x · Cited by 803
Where Does Parkinson Disease Pathology Begin in the Brain?
Del Tredici, K., Rüb, U., de Vos, R. A. I., Bohl, J. R. E., & Braak, H. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.5.413 · Cited by 773
SCHWARTING, R., & HUSTON, J. (1996) · Progress in Neurobiology · doi:10.1016/s0301-0082(96)00040-8 · Cited by 737
Experimental models of Parkinson's disease
Beal, M. F. (2001) · Nature Reviews Neuroscience · doi:10.1038/35072550 · Cited by 637
Jackson-Lewis, V., Jakowec, M., Burke, R. E., & Przedborski, S. (1995) · Neurodegeneration · doi:10.1016/1055-8330(95)90015-2 · Cited by 609
A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter
Liu, Y. (1992) · Cell · doi:10.1016/0092-8674(92)90425-c · Cited by 594
Animal models of Parkinson's disease
Betarbet, R., Sherer, T. B., & Greenamyre, J. T. (2002) · BioEssays · doi:10.1002/bies.10067 · Cited by 592
Przedborski, S., Jackson‐Lewis, V., Naini, A. B., Jakowec, M., Petzinger, G., Miller, R., & Akram, M. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00183.x · Cited by 507
Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization
Hefti, F., Melamed, E., & Wurtman, R. J. (1980) · Brain Research · doi:10.1016/0006-8993(80)90871-9 · Cited by 501
Gerlach, M., & Riederer, P. (1996) · Journal of Neural Transmission · doi:10.1007/bf01291788 · Cited by 498
Tatton, N. A., & Kish, S. J. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00545-3 · Cited by 468
Animal models of neurological deficits: how relevant is the rat?
Cenci, M. A., Whishaw, I. Q., & Schallert, T. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn877 · Cited by 456
Hoffer, B. J., Hoffman, A., Bowenkamp, K., Huettl, P., Hudson, J., Martin, D., Lin, L.-F. H., & Gerhardt, G. A. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90218-6 · Cited by 453
Przedbroski, S., Leviver, M., Jiang, H., Ferreira, M., Jackson-Lewis, V., Donaldson, D., & Togasaki, D. M. (1995) · Neuroscience · doi:10.1016/0306-4522(95)00066-r · Cited by 453
Tranzer, J. P., & Thoenen, H. (1968) · Experientia · doi:10.1007/bf02146956 · Cited by 442
Takahashi, N., Miner, L. L., Sora, I., Ujike, H., Revay, R. S., Kostic, V., Jackson-Lewis, V., Przedborski, S., & Uhl, G. R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.18.9938 · Cited by 429
Ramsay, R. R., & Singer, T. P. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)57434-8 · Cited by 412
Parkinson's Disease in a Chemist Working with 1-Methyl-4-Phenyl-L,2,5,6-Tetrahydropyridine
(1983) · New England Journal of Medicine · doi:10.1056/nejm198308043090511 · Cited by 406
Vila, M., Vukosavic, S., Jackson‐Lewis, V., Neystat, M., Jakowec, M., & Przedborski, S. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.740721.x · Cited by 388
Mechanism of 6-hydroxydopamine neurotoxicity
Glinka, Y., Gassen, M., & Youdim, M. B. H. (1997) · Journal of Neural Transmission. Supplementa · doi:10.1007/978-3-7091-6842-4_7 · Cited by 380
Cleeter, M. W. J., Cooper, J. M., & Schapira, A. H. V. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb09789.x · Cited by 371
Mechanisms of action of 6-hydroxydopamine
Sachs, C., & Jonsson, G. (1975) · Biochemical Pharmacology · doi:10.1016/0006-2952(75)90304-4 · Cited by 357
Locus ceruleus lesions and eosinophilic inclusions in MPTP‐treated monkeys
Forno, L. S., Langston, J. W., DeLanney, L. E., Irwin, I., & Ricaurte, G. A. (1986) · Annals of Neurology · doi:10.1002/ana.410200403 · Cited by 350
Hasegawa, E., Takeshige, K., Oishi, T., Murai, Y., & Minakami, S. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)90498-c · Cited by 319
Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP
Javitch, J. A., & Snyder, S. H. (1984) · European Journal of Pharmacology · doi:10.1016/0014-2999(84)90740-4 · Cited by 317
Bankiewicz, K. S., Oldfield, E. H., Chiueh, C. C., Doppman, J. L., Jacobowitz, D. M., & Kopin, I. J. (1986) · Life Sciences · doi:10.1016/0024-3205(86)90431-5 · Cited by 308
Song, D. D., Shults, C. W., Sisk, A., Rockenstein, E., & Masliah, E. (2004) · Experimental Neurology · doi:10.1016/s0014-4886(03)00342-x · Cited by 295
MPTP Toxicity: Implications for Research in Parkinson's Disease
Kopin, I. J., & Markey, S. P. (1988) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.11.030188.000501 · Cited by 295
Neurochemical findings in the MPTP model of Parkinson's disease
Schmidt, N., & Ferger, B. (2001) · Journal of Neural Transmission · doi:10.1007/s007020100004 · Cited by 290
Localized striatal delivery of GDNF as a treatment for Parkinson disease
Kirik, D., Georgievska, B., & Björklund, A. (2004) · Nature Neuroscience · doi:10.1038/nn1175 · Cited by 290
6-Hydroxydopamine Lesion of the Rat Substantia Nigra: Time Course and Morphology of Cell Death
Jeon, B. S., Jackson-Lewis, V., & Burke, R. E. (1995) · Neurodegeneration · doi:10.1006/neur.1995.0016 · Cited by 289
Przedborski, S., & Vila, M. (2003) · PubMed · Cited by 286
PRZEDBORSKI, S., & VILA, M. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07476.x · Cited by 283
IV. MPTP, MPP+ and mitochondrial function
Nicklas, W. J., Youngster, S. K., Kindt, M. V., & Heikkila, R. E. (1987) · Life Sciences · doi:10.1016/0024-3205(87)90299-2 · Cited by 257
Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo
Hudson, J., Granholm, A.-C., Gerhardt, G. A., Henry, M. A., Hoffman, A., Biddle, P., Leela, N. S., Mackerlova, L., Lile, J. D., Collins, F., et al. (1995) · Brain Research Bulletin · doi:10.1016/0361-9230(94)00224-o · Cited by 242
A 6-hydroxydopamine-induced selective parkinsonian rat model
Perese, D. A., Ulman, J., Viola, J., Ewing, S. E., & Bankiewicz, K. S. (1989) · Brain Research · doi:10.1016/0006-8993(89)90597-0 · Cited by 241
Porter, C. C., Totaro, J. A., & Stone, C. A. (1963) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)26555-7 · Cited by 233
Absence of MPTP-Induced Neuronal Death in Mice Lacking the Dopamine Transporter
Bezard, E., Gross, C. E., Fournier, M.-C., Dovero, S., Bloch, B., & Jaber, M. (1999) · Experimental Neurology · doi:10.1006/exnr.1998.6995 · Cited by 230
Andrew, R., Watson, D. G., Best, S. A., Midgley, J. M., Wenlong, H., & Petty, R. K. H. (1993) · Neurochemical Research · doi:10.1007/bf00978370 · Cited by 225
Mizuno, Y., Sone, N., & Saitoh, T. (1987) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1987.tb05737.x · Cited by 221
The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice
Sonsalla, P. K., & Heikkila, R. E. (1986) · European Journal of Pharmacology · doi:10.1016/0014-2999(86)90444-9 · Cited by 211
Forno, L. S., DeLanney, L. E., Irwin, I., & Langston, J. W. (1993) · PubMed · Cited by 207
Free Radical‐Generated Neurotoxicity of 6‐Hydroxydopamine
Kumar, R., Agarwal, A. K., & Seth, P. K. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64041703.x · Cited by 202
Intranigral Iron Injection Induces Behavioral and Biochemical “Parkinsonism” in Rats
Ben‐Shachar, D., & Youdim, M. B. H. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb06432.x · Cited by 197
Interdependence of the Nigrostriatal Dopaminergic Systems on the Two Sides of the Brain in the Cat
Nieoullon, A., Chéramy, A., & Glowinski, J. (1977) · Science · doi:10.1126/science.910137 · Cited by 183
Luthman, J., Fredriksson, A., Sundström, E., JONSSON, G., & Archer, T. (1989) · Behavioural Brain Research · doi:10.1016/s0166-4328(89)80121-4 · Cited by 169
Changes in dopamine levels in the corpus striatum following lesions in the substantia nigra
Faull, R. L. M., & Laverty, R. (1969) · Experimental Neurology · doi:10.1016/0014-4886(69)90081-8 · Cited by 165
Bezard, E., Imbert, C., Deloire, X., Bioulac, B., & Gross, C. E. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00531-3 · Cited by 165
Chemical, Enzymatic and Metabolic Studies on the Mechanism of Oxidation of Dopamine1
Senoh, S., Creveling, C. R., Udenfriend, S., & Witkop, B. (1959) · Journal of the American Chemical Society · doi:10.1021/ja01532a030 · Cited by 163
Cadet, J. L., Katz, M., Jackson-Lewis, V., & Fahn, S. (1989) · Brain Research · doi:10.1016/0006-8993(89)91530-8 · Cited by 163
6-Hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: The turning syndrome
Ungerstedt, U. (1976) · Pharmacology & Therapeutics Part B General and Systematic Pharmacology · doi:10.1016/0306-039x(76)90016-7 · Cited by 150
Berger, K., Przedborski, S., & Cadet, J. L. (1991) · Brain Research Bulletin · doi:10.1016/0361-9230(91)90242-c · Cited by 147
Giovanni, A., Sieber, B.-A., Heikkila, R. E., & Sonsalla, P. K. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22503-4 · Cited by 140
Mayer, R. A., Kindt, M. V., & Heikkila, R. E. (1986) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1986.tb00722.x · Cited by 139
Perumal, A. S., Gopal, V. B., Tordzro, W. K., Cooper, T. B., & Cadet, J. L. (1992) · Brain Research Bulletin · doi:10.1016/0361-9230(92)90142-k · Cited by 120 · cited 4×
“…pretreatment with iron chelating compounds, vitamin E, or sellegine, a monoamine oxidase B (MAO-B) inhibitor, may also be considered as indirect evidence for the production of free radicals and involvement of oxidative stress mechanisms (Knoll 1986; Cadet et al. 1989; Perumal et al. 1992).”
BackgroundInfluentialMPP+ and MPDP+ induced oxygen radical formation with mitochondrial enzymes
Adams, J. D., Jr., Klaidman, L. K., & Leung, A. C. (1993) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(93)90057-2 · Cited by 118
Giovanni, A., Sonsalla, P. K., & Heikkila, R. E. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22504-6 · Cited by 117
Porter, C. C., Totaro, J. A., & Burcin, A. (1965) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)27139-7 · Cited by 111
Lindner, M. D., Cain, C. K., Plone, M. A., Frydel, B. R., Blaney, T. J., Emerich, D. F., & Hoane, M. R. (1999) · Behavioural Brain Research · doi:10.1016/s0166-4328(98)00160-0 · Cited by 107
Animal models of Parkinson’s disease in rodents induced by toxins: an update
Hirsch, É. C., Höglinger, G. U., Rousselet, E., Breidert, T., Parain, K., Féger, J., Ruberg, M., Prigent, A., Cohen‐Salmon, C., & Launay, J. (2003) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-0643-3_6 · Cited by 105
Schneider, J. S., & Roeltgen, D. P. (1993) · Brain Research · doi:10.1016/0006-8993(93)90049-s · Cited by 105
Reinhard, J. F., Diliberto, E. J., Viveros, O. H., & Daniels, A. J. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.22.8160 · Cited by 102
Orth, M., & Tabrizi, S. J. (2003) · Movement Disorders · doi:10.1002/mds.10447 · Cited by 97
Non-enzymatic Conversions of Dopamine to Norepinephrine and Trihydroxyphenethylamines1
Senoh, S., & Witkop, B. (1959) · Journal of the American Chemical Society · doi:10.1021/ja01532a028 · Cited by 93
Kinetics of nigral degeneration in a chronic model of MPTP-treated mice
Bézard, E., Doveró, S., Bioulac, B. H., & Gross, C. E. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00663-0 · Cited by 91
Klaidman, L. K., Adams, J. D., Jr., Leung, A. C., Kim, S. S., & Cadenas, E. (1993) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(93)90056-z · Cited by 87
Schneider, J. S., Tinker, J. P., Velson, M. V., Menzaghi, F., & Lloyd, G. K. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)34957-2 · Cited by 86
Selective MPP+ uptake into synaptic dopamine vesicles: possible involvement in MPTP neurotoxicity
Zompo, M. D., Piccardi, M. P., Ruiu, S., Quartu, M., GESSA, G. L., & Vaccari, A. (1993) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1993.tb13584.x · Cited by 69
The pharmacology of (-)deprenyl.
Knoll, J. E. (1986) · PubMed · Cited by 64
GDNF: a cytokine at the interface of TGF-βs and neurotrophins
Unsicker, K. (1996) · Cell and Tissue Research · doi:10.1007/s004410050686 · Cited by 56
Intracranial delivery of proteins and peptides as a therapy for neurodegenerative diseases
Grondin, R., Zhang, Z., Ai, Y., Gash, D. M., & Gerhardt, G. A. (2003) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8049-7_4 · Cited by 43
Ipsilateral and contralateral subthalamic activity after unilateral dopaminergic lesion
Perier, C., Agid, Y., Hirsch, É. C., & Féger, J. (2000) · Neuroreport · doi:10.1097/00001756-200009280-00045 · Cited by 43
Thoenen, H. (1972) · Springer eBooks · doi:10.1007/978-3-642-65249-3_18 · Cited by 42
Salin, P., Hajji, M. D., & Goff, L. K. (1996) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1996.tb01318.x · Cited by 39
Przedborski, S., Jackson-Lewis, V. R., Popilskis, S. J., Kostić, V., Levivier, M., Fahn, S., & Cadet, J. L. (1991) · PubMed · Cited by 37
Unsicker, K., Allan, I. J., & Newgreen, D. F. (1976) · Cell and Tissue Research · doi:10.1007/bf00219265 · Cited by 18
Gee, P., San, R. H. C., Davison, A. J., & STICH, H. F. (1992) · Free Radical Research Communications · doi:10.3109/10715769209049153 · Cited by 15
Extraneuronal effects of 6-hydroxydopamine: Tissue culture studies on adrenocortical cells of rats
Unsicker, K., Chamley, J., & McLean, J. G. (1976) · Cell and Tissue Research · doi:10.1007/bf00222152 · Cited by 6
Langston, J. W., Forno, L. S., Tetrud, J., Reeves, A. G., Kaplan, J. A., & Karluk, D. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199910)46:4 · Cited by 1
Cited by
Pathological roles of MAPK signaling pathways in human diseases
Kim, E. K., & Choi, E.-J. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.12.009 · Cited by 2,472
Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications
Pajares, M., I. Rojo, A., Manda, G., Boscá, L., & Cuadrado, A. (2020) · Cells · doi:10.3390/cells9071687 · Cited by 779
Parkinson's disease: Mechanisms, translational models and management strategies
Raza, C., Anjum, R., & Shakeel, N. U. A. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.03.057 · Cited by 603
Microglia in Neuroinflammation and Neurodegeneration: From Understanding to Therapy
Muzio, L., Viotti, A., & Martino, G. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.742065 · Cited by 581
Adibhatla, R. M., & Hatcher, J. F. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2668 · Cited by 480
Metadata
- Authors
- Schober, A.
- Venue
- Cell and Tissue Research
- Published
- 2004-07-28
- Volume
- 318
- Issue
- 1
- Pages
- 215-224
- ISSN
- 0302-766X (ISSN-L)
- 1432-0878
- OpenAlex
- W2046632451
- Cited by
- 803
- References
- 90
- FWCI
- 14.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.